Insider · CIK 0002035647
Anna Rivkin
Files at FHTX (Foghorn Therapeutics Inc.). First filing -, latest -.
In brief
Anna Rivkin files SEC Form 4 as officer at FHTX (Foghorn Therapeutics Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Anna Rivkin has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 2 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 30, 2026 | FHTX Foghorn Therapeutics Inc. | AGrant or award Stock option (right to buy)derivative | +165,000 | $5.71 | $942k | 165,000 | Feb 2, 2026 |
| Jan 22, 2025 | FHTX Foghorn Therapeutics Inc. | AGrant or award Stock Option (right to buy)derivative | +50,000 | $4.37 | $219k | 50,000 | Jan 24, 2025 |
Questions about Anna Rivkin
Answered from the filings on this page, as of the latest one.
Is Anna Rivkin buying or selling?
Anna Rivkin has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Anna Rivkin's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Anna Rivkin has 0.
Where does Anna Rivkin file Form 4?
Anna Rivkin has filed Form 4 at FHTX (Foghorn Therapeutics Inc.) as Chief Business Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.